|
ATE306930T1
(de)
*
|
1994-08-12 |
2005-11-15 |
Immunomedics Inc |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US6395276B1
(en)
*
|
1997-05-02 |
2002-05-28 |
Immunomedics, Inc. |
Immunotoxins directed against malignant cells
|
|
US6653104B2
(en)
*
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
CA2269060C
(en)
*
|
1996-10-17 |
2009-04-07 |
Immunomedics, Inc. |
Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
|
|
DE69837095T2
(de)
*
|
1997-09-03 |
2007-11-22 |
Immunomedics, Inc. |
Fluorierung von proteinen und peptiden für positronemissionstomographie
|
|
EP1045861B1
(en)
*
|
1998-01-15 |
2009-03-04 |
Center For Molecular Medicine And Immunology |
Bispecific targeting moiety comprising an antibody to carcinoembryonic antigen (cea) and the ligand-binding region of the il13 receptor alpha subunit
|
|
US6703488B1
(en)
|
1998-01-15 |
2004-03-09 |
Center For Molecular Medicine And Immunology |
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
|
US6869604B1
(en)
*
|
1998-03-27 |
2005-03-22 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant anti-tumor RNAse
|
|
KR20020027311A
(ko)
|
1999-05-07 |
2002-04-13 |
제넨테크, 인크. |
Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
|
|
US6949520B1
(en)
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
|
US7045283B2
(en)
*
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
|
IL160358A0
(en)
*
|
2001-08-23 |
2004-07-25 |
Genmab As |
Human antibodies specific for interleukin 15 (il-15)
|
|
US7247304B2
(en)
*
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
|
US7329405B2
(en)
*
|
2001-08-23 |
2008-02-12 |
Genmab A/S |
Human antibodies specific for interleukin 15 (IL-15)
|
|
AU2003201559A1
(en)
*
|
2002-01-14 |
2003-07-24 |
William Herman |
Multispecific binding molecules
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
|
GB0308731D0
(en)
*
|
2003-04-15 |
2003-05-21 |
Anticancer Therapeutic Inv Sa |
Method of radiotherapy
|
|
JP2007524412A
(ja)
*
|
2004-01-22 |
2007-08-30 |
イムノメディクス， インコーポレイテッド |
葉酸コンジュゲートおよびコンプレックス
|
|
US8470315B2
(en)
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
AU2005335217A1
(en)
*
|
2004-10-05 |
2007-02-15 |
Ochsner Clinic Foundation |
Enhancement of B cell proliferation by IL-15
|
|
EA015584B1
(ru)
|
2005-03-23 |
2011-10-31 |
Генмаб А/С |
Антитело к cd38 человека и его применение
|
|
AU2006285278B2
(en)
|
2005-08-31 |
2011-05-12 |
Immunomedics, Inc. |
F-18 peptides for pre targeted positron emission tomography imaging
|
|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
JP2009541333A
(ja)
*
|
2006-06-23 |
2009-11-26 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
修飾リボヌクレアーゼ
|
|
EP2049151A4
(en)
|
2006-07-17 |
2010-03-24 |
Quintessence Biosciences Inc |
METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
|
HRP20191115T1
(hr)
|
2006-09-26 |
2019-09-20 |
Genmab A/S |
Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
|
|
JPWO2008133141A1
(ja)
*
|
2007-04-24 |
2010-07-22 |
東洋紡績株式会社 |
オスモチン組換えタンパク質およびその製造方法、並びにその利用
|
|
CA2698343C
(en)
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
CA2702043A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
|
PT4160212T
(pt)
|
2008-01-15 |
2024-06-25 |
Univ Leland Stanford Junior |
Marcadores de células estaminais de leucemia mielóide aguda
|
|
US11072655B2
(en)
|
2008-01-15 |
2021-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
|
PT3056515T
(pt)
|
2008-01-15 |
2019-07-19 |
Univ Leland Stanford Junior |
Métodos para manipulação da fagocitose mediada por cd47
|
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
|
EP2334695B1
(en)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutic ribonucleases
|
|
HRP20230487T1
(hr)
|
2009-02-13 |
2023-07-21 |
Immunomedics, Inc. |
Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti
|
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
GB0905438D0
(en)
*
|
2009-03-30 |
2009-05-13 |
Ge Healthcare Ltd |
Radiolabelling reagents and methods
|
|
EP2419449A1
(en)
*
|
2009-04-16 |
2012-02-22 |
Charité Universitätsmedizin Berlin |
B-lymphocyte targeting agents for use in a method for the treatment of a disease
|
|
WO2011053982A2
(en)
|
2009-11-02 |
2011-05-05 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
|
US8772459B2
(en)
|
2009-12-02 |
2014-07-08 |
Imaginab, Inc. |
J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
|
|
GB201002508D0
(en)
|
2010-02-12 |
2010-03-31 |
Algeta As |
Product
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
JP6063450B2
(ja)
|
2011-04-29 |
2017-01-18 |
ユニヴァーシティ オブ ワシントン |
治療用ヌクレアーゼ組成物および方法
|
|
JP6024025B2
(ja)
|
2011-05-02 |
2016-11-09 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
少容量投与用のアロタイプ選択抗体の限外濾過濃縮
|
|
SG11201405468QA
(en)
|
2012-03-14 |
2014-10-30 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
WO2013188740A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
|
PL2900277T3
(pl)
|
2012-12-13 |
2022-05-16 |
Immunomedics, Inc. |
Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
|
|
US11559580B1
(en)
|
2013-09-17 |
2023-01-24 |
Blaze Bioscience, Inc. |
Tissue-homing peptide conjugates and methods of use thereof
|
|
HRP20192080T1
(hr)
|
2013-10-31 |
2020-02-07 |
Resolve Therapeutics, Llc |
Terapeutske fuzije nukleaza-albumine i postupci
|
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
MY192918A
(en)
|
2014-09-09 |
2022-09-15 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
AU2015328370B2
(en)
|
2014-10-07 |
2021-08-05 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
EP3227338A4
(en)
|
2014-12-04 |
2018-05-16 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of acute myeloid leukemia
|
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
MY192978A
(en)
|
2015-06-22 |
2022-09-20 |
Janssen Biotech Inc |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
KR20180025865A
(ko)
|
2015-07-06 |
2018-03-09 |
리제너론 파마슈티칼스 인코포레이티드 |
다중특이적 항원 결합 분자 및 이의 용도
|
|
ES3020458T3
(en)
|
2015-08-07 |
2025-05-22 |
Imaginab Inc |
Antigen binding constructs to target molecules
|
|
CN108135970B
(zh)
|
2015-09-09 |
2023-09-01 |
弗莱德哈钦森癌症中心 |
软骨归巢肽
|
|
PL3827845T3
(pl)
|
2015-11-03 |
2022-07-11 |
Janssen Biotech, Inc. |
Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
US11352446B2
(en)
|
2016-04-28 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
DK3478830T3
(da)
|
2016-07-01 |
2024-05-21 |
Resolve Therapeutics Llc |
Optimerede binucleasefusioner og metoder
|
|
AU2018210157B2
(en)
|
2017-01-18 |
2022-10-06 |
Fred Hutchinson Cancer Center |
Peptide compositions and methods of use thereof for disrupting TEAD interactions
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
EP3595699A4
(en)
|
2017-03-16 |
2020-12-23 |
Blaze Bioscience, Inc. |
PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
|
|
WO2018222675A1
(en)
|
2017-05-30 |
2018-12-06 |
The Board Of Regents Of The University Of Oklahoma |
Anti-doublecortin-like kinase 1 antibodies and methods of use
|
|
CN110809583A
(zh)
|
2017-06-07 |
2020-02-18 |
瑞泽恩制药公司 |
用于内化酶的组合物和方法
|
|
CA3064436A1
(en)
|
2017-06-15 |
2018-12-20 |
Blaze Bioscience, Inc. |
Renal-homing peptide conjugates and methods of use thereof
|
|
JP7374091B2
(ja)
|
2017-08-22 |
2023-11-06 |
サナバイオ， エルエルシー |
可溶性インターフェロン受容体およびその使用
|
|
CA3079242A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
AU2018388583A1
(en)
|
2017-12-19 |
2020-06-11 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
KR20200118151A
(ko)
|
2018-02-07 |
2020-10-14 |
리제너론 파마슈티칼스 인코포레이티드 |
치료 단백질 전달을 위한 방법 및 조성물
|
|
MX2020012350A
(es)
|
2018-05-17 |
2021-01-29 |
Regeneron Pharma |
Anticuerpos anti-cd63, conjugados y usos de estos.
|
|
WO2021050789A1
(en)
|
2019-09-10 |
2021-03-18 |
Obsidian Therapeutics, Inc. |
Ca2-il15 fusion proteins for tunable regulation
|
|
US12043671B2
(en)
|
2021-06-16 |
2024-07-23 |
Gundersen Lutheran Medical Foundation, Inc. |
Antibodies targeting an amphiregulin-derived cell surface neo-epitope
|